22 April 2024>: Clinical Research
Predicting Acute Cardiovascular Complications in COVID-19: Insights from a Specialized Cardiac Referral Department
Michał Machowski 1ABCDEF , Aisha Ou-Pokrzewińska 1BCDEF , Katarzyna Perzanowska-Brzeszkiewicz 1BCDEF , Magdalena Gałecka-Nowak 1BDE , Szymon Pacho 1BDE , Mateusz Jermakow 1BCDE* , Agnieszka Wójcik 1BDE , Milena Zoruk 1BDE , Andrzej Pruszczyk 1BDE , Karol Deutsch 1BDE , Marek Roik 1BDE , Andrzej Łabyk 1BDE , Piotr Palczewski 2ABDEF , Piotr Pruszczyk 1ABCDEFDOI: 10.12659/MSM.942612
Med Sci Monit 2024; 30:e942612
Table 1 Initial clinical and laboratory characteristics of total study group.
Parameter [unit] | Value |
---|---|
Age [years] | 68.1 (13.9) |
Male sex, n (%) | 159 (63.9) |
Previous CAD, n (%) | 60 (24.1) |
Previous CHF, n (%) | 51 (20.5) |
COVID-19 pneumonia lung involvement [%] | 50.4 (24.9) |
Procalcitonin [ng/ml] | 0.18 (0.08;0.50) |
CRP [mg/dl] | 79.1 (34.73;147.8) |
MEWS | 1.00 (1.00;2.00) |
CAD – coronary artery disease; CHF – congestive heart failure; CRP – C-reactive protein; MEWS – Modified Early Warning Score. |